Many people with obesity, prediabetes, or metabolic syndrome develop elevated triglycerides without realizing it, since high triglycerides rarely cause noticeable symptoms
SGLT-2 inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors dominate prescribing volumes, supported by an 87.5% medication adherence rate among older adults
These medications work by mimicking the bodys natural glucagon-like peptide-1, a hormone that regulates appetite and blood sugar
Zepbound is often placed on the same tier as Wegovy and requires similar prior authorization criteria
The role of methionine on metabolism, oxidative stress, and diseases
Studies with longer follow-up duration are required to further investigate the potential factors associated with weight change after discontinuation of treatment